ABBV vs JNJ
AbbVie Inc. and Johnson & Johnson, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | ABBV | JNJ |
|---|---|---|
| Revenue | $61.2B | $94.2B |
| Net income | $4.2B | $26.8B |
| Gross margin | 70.2% | 67.9% |
| Net margin | 6.9% | 28.5% |
| Return on equity | · | 35.0% |
| Diluted EPS | $2.36 | $11.03 |
| Dividend / share | $6.65 | $5.14 |
| Payout ratio | 275.8% | · |
| Free cash flow | $17.8B | $19.7B |
| Equity | $-3.3B | · |
| Net debt / equity | · | 0.27× |
| Current ratio | 0.67× | 1.03× |
| Revenue CAGR 5y | 6.0% | 2.7% |
| Profit CAGR 5y | −1.7% | 12.7% |
JNJ bills 1.5× the revenue of ABBV, and keeps more of each dollar of revenue as profit (28.5% against 6.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ABBV | JNJ |
|---|---|---|
| FY2025 | $61.2B | $94.2B |
| FY2024 | $56.3B | $88.8B |
| FY2023 | $54.3B | $85.2B |
| FY2022 | $58.1B | $80.0B |
| FY2021 | $56.2B | $78.7B |
| FY2020 | $45.8B | $82.6B |
| FY2019 | $33.3B | $82.1B |
| FY2018 | $32.8B | $81.6B |
| FY2017 | $28.2B | $76.5B |
| FY2016 | $25.6B | $71.9B |
Bottom line
| Fiscal year | ABBV | JNJ |
|---|---|---|
| FY2025 | $4.2B | $26.8B |
| FY2024 | $4.3B | $14.1B |
| FY2023 | $4.9B | $35.2B |
| FY2022 | $11.8B | $17.9B |
| FY2021 | $11.5B | $20.9B |
| FY2020 | $4.6B | $14.7B |
| FY2019 | $7.9B | $15.1B |
| FY2018 | $5.7B | $15.3B |
| FY2017 | $5.3B | $1.3B |
| FY2016 | $6.0B | $16.5B |
15 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$33,033,000,000 | JNJ |
| FY2024 | −$32,487,000,000 | JNJ |
| FY2023 | −$30,841,000,000 | JNJ |
| FY2022 | −$21,936,000,000 | JNJ |
| FY2021 | −$22,543,000,000 | JNJ |
| FY2020 | −$36,780,000,000 | JNJ |
| FY2019 | −$48,793,000,000 | JNJ |
| FY2018 | −$48,828,000,000 | JNJ |
| FY2017 | −$48,234,000,000 | JNJ |
| FY2016 | −$46,252,000,000 | JNJ |
| FY2015 | −$47,215,000,000 | JNJ |
| FY2014 | −$54,371,000,000 | JNJ |
| FY2013 | −$52,522,000,000 | JNJ |
| FY2012 | −$48,844,000,000 | JNJ |
| FY2011 | −$47,586,000,000 | JNJ |
JNJ has reported the higher revenue in every one of these 15 fiscal years. The gap has narrowed since the earliest year compared.
15 of 19 comparable fiscal years — a year missing data on either side is not counted.
12 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −21.5 pp | JNJ |
| FY2024 | −8.2 pp | JNJ |
| FY2023 | −32.3 pp | JNJ |
| FY2022 | −2.0 pp | JNJ |
| FY2021 | −6.0 pp | JNJ |
| FY2020 | −7.7 pp | JNJ |
| FY2019 | +5.3 pp | ABBV |
| FY2018 | −1.4 pp | JNJ |
| FY2017 | +17.1 pp | ABBV |
| FY2016 | +0.2 pp | ABBV |
| FY2015 | +0.5 pp | ABBV |
| FY2014 | −13.1 pp | JNJ |
The higher net margin has changed hands between ABBV and JNJ over this period.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
JNJ's net margin has been more volatile than ABBV's over the 12 comparable fiscal years — 8.8 percentage points of standard deviation against 6.4.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ABBV and JNJ over these 12 fiscal years — ABBV led in 4 and JNJ in 8.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ABBV's return on equity has been more volatile than JNJ's over the 8 comparable fiscal years — 45.0 percentage points of standard deviation against 11.9.
8 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between ABBV and JNJ over these 8 fiscal years — ABBV led in 7 and JNJ in 1.
8 of 19 comparable fiscal years — a year missing data on either side is not counted.